Cargando…

Non-concealed placebo treatment for menopausal hot flushes: Study protocol of a randomized-controlled trial

BACKGROUND: Beneficial effects of placebos are high in double-blind hot flush trials. Studies in various conditions suggest that honestly prescribed placebos may elicit symptom improvement. OBJECTIVE: To determine whether open label placebo (OLP) treatment is efficacious in alleviating hot flushes a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yiqi, Meister, Ramona, Löwe, Bernd, Winkelmann, Anne, Kaptchuk, Ted J., Buhling, Kai J., Nestoriuc, Yvonne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697911/
https://www.ncbi.nlm.nih.gov/pubmed/31420050
http://dx.doi.org/10.1186/s13063-019-3575-1
_version_ 1783444449985036288
author Pan, Yiqi
Meister, Ramona
Löwe, Bernd
Winkelmann, Anne
Kaptchuk, Ted J.
Buhling, Kai J.
Nestoriuc, Yvonne
author_facet Pan, Yiqi
Meister, Ramona
Löwe, Bernd
Winkelmann, Anne
Kaptchuk, Ted J.
Buhling, Kai J.
Nestoriuc, Yvonne
author_sort Pan, Yiqi
collection PubMed
description BACKGROUND: Beneficial effects of placebos are high in double-blind hot flush trials. Studies in various conditions suggest that honestly prescribed placebos may elicit symptom improvement. OBJECTIVE: To determine whether open label placebo (OLP) treatment is efficacious in alleviating hot flushes among peri- and postmenopausal women. METHODS/DESIGN: In this assessor-blinded, randomized-controlled trial, n = 100 women experiencing five or more daily hot flushes of at least moderate severity and bothersomeness are assigned 1:1 to a 4-week OLP treatment or no treatment. To explore the duration and maintenance of placebo effects, the OLP group is randomized a second time to either discontinue or continue the OLP treatment for another 4 weeks. All participants receive a briefing about placebo effects and study visits at baseline, post-treatment (4 weeks), and follow-up (8 weeks, OLP group only). Qualitative interviews about subjective experiences with the OLP treatment are conducted. Primary outcomes are differences between the OLP and the no-treatment group in the hot flush composite score (frequency × severity), and bothersomeness of hot flushes as assessed with the Hot Flush Rating Scale at post-treatment. Secondary outcomes include hot flush frequency, health-related quality of life, global improvement, and the number of responders at post-treatment. Data are analyzed by fitting (generalized) linear mixed models. An exploratory analysis of maintenance and duration is performed including follow-up data. DISCUSSION: This trial will contribute to the evaluation of OLP treatments in clinical practice and further our understanding about the magnitude of placebo effects in hot flush treatments. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03838523. Retrospectively registered on February 12th, 2019. The first patient was enrolled on October 10th, 2018.
format Online
Article
Text
id pubmed-6697911
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66979112019-08-19 Non-concealed placebo treatment for menopausal hot flushes: Study protocol of a randomized-controlled trial Pan, Yiqi Meister, Ramona Löwe, Bernd Winkelmann, Anne Kaptchuk, Ted J. Buhling, Kai J. Nestoriuc, Yvonne Trials Study Protocol BACKGROUND: Beneficial effects of placebos are high in double-blind hot flush trials. Studies in various conditions suggest that honestly prescribed placebos may elicit symptom improvement. OBJECTIVE: To determine whether open label placebo (OLP) treatment is efficacious in alleviating hot flushes among peri- and postmenopausal women. METHODS/DESIGN: In this assessor-blinded, randomized-controlled trial, n = 100 women experiencing five or more daily hot flushes of at least moderate severity and bothersomeness are assigned 1:1 to a 4-week OLP treatment or no treatment. To explore the duration and maintenance of placebo effects, the OLP group is randomized a second time to either discontinue or continue the OLP treatment for another 4 weeks. All participants receive a briefing about placebo effects and study visits at baseline, post-treatment (4 weeks), and follow-up (8 weeks, OLP group only). Qualitative interviews about subjective experiences with the OLP treatment are conducted. Primary outcomes are differences between the OLP and the no-treatment group in the hot flush composite score (frequency × severity), and bothersomeness of hot flushes as assessed with the Hot Flush Rating Scale at post-treatment. Secondary outcomes include hot flush frequency, health-related quality of life, global improvement, and the number of responders at post-treatment. Data are analyzed by fitting (generalized) linear mixed models. An exploratory analysis of maintenance and duration is performed including follow-up data. DISCUSSION: This trial will contribute to the evaluation of OLP treatments in clinical practice and further our understanding about the magnitude of placebo effects in hot flush treatments. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03838523. Retrospectively registered on February 12th, 2019. The first patient was enrolled on October 10th, 2018. BioMed Central 2019-08-16 /pmc/articles/PMC6697911/ /pubmed/31420050 http://dx.doi.org/10.1186/s13063-019-3575-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Pan, Yiqi
Meister, Ramona
Löwe, Bernd
Winkelmann, Anne
Kaptchuk, Ted J.
Buhling, Kai J.
Nestoriuc, Yvonne
Non-concealed placebo treatment for menopausal hot flushes: Study protocol of a randomized-controlled trial
title Non-concealed placebo treatment for menopausal hot flushes: Study protocol of a randomized-controlled trial
title_full Non-concealed placebo treatment for menopausal hot flushes: Study protocol of a randomized-controlled trial
title_fullStr Non-concealed placebo treatment for menopausal hot flushes: Study protocol of a randomized-controlled trial
title_full_unstemmed Non-concealed placebo treatment for menopausal hot flushes: Study protocol of a randomized-controlled trial
title_short Non-concealed placebo treatment for menopausal hot flushes: Study protocol of a randomized-controlled trial
title_sort non-concealed placebo treatment for menopausal hot flushes: study protocol of a randomized-controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697911/
https://www.ncbi.nlm.nih.gov/pubmed/31420050
http://dx.doi.org/10.1186/s13063-019-3575-1
work_keys_str_mv AT panyiqi nonconcealedplacebotreatmentformenopausalhotflushesstudyprotocolofarandomizedcontrolledtrial
AT meisterramona nonconcealedplacebotreatmentformenopausalhotflushesstudyprotocolofarandomizedcontrolledtrial
AT lowebernd nonconcealedplacebotreatmentformenopausalhotflushesstudyprotocolofarandomizedcontrolledtrial
AT winkelmannanne nonconcealedplacebotreatmentformenopausalhotflushesstudyprotocolofarandomizedcontrolledtrial
AT kaptchuktedj nonconcealedplacebotreatmentformenopausalhotflushesstudyprotocolofarandomizedcontrolledtrial
AT buhlingkaij nonconcealedplacebotreatmentformenopausalhotflushesstudyprotocolofarandomizedcontrolledtrial
AT nestoriucyvonne nonconcealedplacebotreatmentformenopausalhotflushesstudyprotocolofarandomizedcontrolledtrial